In newborns, macrophages perform a process called efferocytosis, which recognizes and eats dying cells. This process triggers the production of a bioactive lipid called thromboxane, signaling nearby ...

Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Singh, A. , Sinha, R. , Saran, M. , Kazmi, D. , Gupta, H. and Seth, G. (2025) Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One ...

Subjects received either a daily dose of either 100mg (low dose) or 300mg (high dose) of the oral thromboxane receptor antagonist ifetroban or a placebo. Improvement in the heart’s left ventricular ...

DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Patients with DMD slowly lose muscle ...

Similarly, derivative markers measured in blood, thromboxane B2 (platelet activation) and Thrombin-Antithrombin III complexes (coagulation activation), were also significantly reduced in the P8RI-SV ...

US-based pharmaceutical company Cumberland Pharmaceuticals has reported positive top-line outcomes from a Phase II trial of ifetroban as a potential treatment for Duchenne muscular dystrophy (DMD).

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...

1 Department of Pharmacology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy 2 Department of Thoracic Medicine, Imperial College School of Medicine at the National Heart and ...

Bioluminescence resonance energy transfer (BRET) is a biophysical technique used to monitor proximity within live cells. BRET exploits the naturally occurring phenomenon of dipole-dipole energy ...